Host Based Diagnostics for Acute Infections
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Army's Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) is conducting market research through a Request for Information (RFI) for Host Based Diagnostics for Acute Infections. This initiative seeks to develop next-generation host-based assays for diagnosing disease etiology, prognosing clinical outcomes, and directing therapeutic treatments to protect warfighters from chemical, biological, radiological, and nuclear (CBRN) threats. Responses are due May 22, 2026.
Scope of Work
CPE CBRND is seeking innovative solutions that diagnose infection based on the body's response (host biomarkers) rather than targeting specific pathogens. Key areas of interest include:
- Predictive Diagnostics for Infection Complications: Assays that predict conditions like Sepsis, SIRS, respiratory destabilization, or other acute complications from infections.
- Diagnostics to assist in Therapeutic Selection and Monitoring: Host biomarker-based diagnostics that enable precision medicine for appropriate treatment or monitor therapeutic response. Desired products should be at Technology Readiness Level (TRL) 4 or higher, be small (handheld/backpack-sized), battery-operable, operate in tropical humidity and temperature environments, have an assay time under 70 minutes (ideally <10 minutes), and demonstrate clinical sensitivity and specificity greater than 90%. Sample types include peripheral blood, fingerstick blood, or respiratory samples.
Contract & Timeline
- Type: Sources Sought / Request for Information (RFI)
- Set-Aside: None specified (market research stage)
- Response Due: May 22, 2026
- Published: April 23, 2026
Evaluation
This RFI supports the existing Advanced Differential Diagnostics (ADD) program. The government will place the greatest emphasis on the "Technical Approach and Product Maturity" and "Regulatory and Clinical Status" sections of submitted white papers, seeking detailed, data-driven evidence. Responses will help shape the future of military medicine.
Additional Notes
This is for planning purposes only and does not constitute a solicitation or commitment to contract. Respondents must submit a white paper (max 3 pages) and a one-page Quad Chart to mcdc@ati.org. Do not include proprietary or classified information.